Rein therapeutics and qureight ltd announce planned integration of deep-learning platform for phase 2 trial of lti-03 in patients with ipf

Austin, texas , may 1, 2025 /prnewswire/ -- rein therapeutics ("rein") (nasdaq: rntx), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, and qureight ltd, a core imaging laboratory developing deep-learning image analytics, today announced a collaboration for the integration of qureight's deep-learning platform into rein's planned phase 2 trial of its lead asset lti-03, a novel, multi-pathway, caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis (ipf). rein previously announced positive topline results from cohort 2 (5 mg bid) of the phase 1b clinical trial of lti-03 in ipf, in which a positive trend was observed in seven out of eight biomarkers evaluated, with five biomarkers demonstrating dose-dependent effects and four biomarkers achieving statistical significance in the combined cohort 1 and cohort 2 data set.
RNTX Ratings Summary
RNTX Quant Ranking